StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / kalocyte.com

KaloCyte

KaloCyte (kalocyte.com): 2 changes recorded in its website history since March 2018. Homepage last checked 6 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. HeadlineBetween and
    BeforeDEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION
    AfterDiscover ErythroMer™

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  2. HeadlineBetween and
    BeforeA revolution in trauma care
    AfterDEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 21 March 2018

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

A revolution in trauma care

Accuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. February 2025 – November 2026 · 4 captures · latest observed messagingDiscover ErythroMer™

    KaloCyte is developing ErythroMer™, a dried, bio-inspired artificial red blood cell, to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable or in short supply.

    This wording observed 6 November 2026.

    current websiteHistorical capture not publicly available
    Inspect 4 captures in this group
  2. July 2019 – January 2024 · 6 capturesDEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION

    This wording observed 5 January 2024.

    archived page
    Inspect 6 captures in this group
    • 5 July 2019 · DEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION archived page
    • 5 January 2020 · DEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION archived page
    • 24 October 2021 · DEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION archived page
    • 7 August 2022 · DEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION archived page
    • 7 March 2023 · DEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION archived page
    • 5 January 2024 · DEVELOPING A SOLUTION FOR WHEN BLOOD IS NOT AN OPTION archived page
  3. Seen March 2018 · 1 captureA revolution in trauma care

    Accuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk

    This wording observed 21 March 2018.

    archived page

Cite this record

StartupHistory, “KaloCyte” company record, https://startuphistory.org/c/kalocyte.com

Machine-readable: /c/kalocyte.com.json. How changes are found: method.